Background: Tocilizumab (TCZ) is indicated for RA patients with inadequate responses to DMARDs, either as monotherapy (Mono) or in combination with DMARDs (Combo). ACT-UP pools data from several international, observational, post-marketing studies of i.v. TCZ. Interim observations of patterns of TCZ-use in RA patients, adherence to label recommendations and safety are reported. Methods: Adult patients with moderate-to-severe RA who started TCZ in routine practice were observed in clinical practice for 6 months. There were no specified dosing regimens (concomitant RA treatments permitted) and no interventional procedures, clinic visits, or laboratory analyses outside routine practice. Results: Data are reported for 961 patients receiving TCZ [352 (37%) initiated as Mono and 609 (63%) as Combo]. 94% and 95% of Mono and Combo patients, respectively, started TCZ at 8 mg/kg, and 93% and 94% of patients, respectively, taking TCZ at 6 months received 8 mg/kg. TCZ dose changes occurred in 34 (10%) Mono patients (7 increased, 11 decreased, 16 increased and decreased) and 68 (11%) Combo patients (13 increased, 20 decreased, 35 increased and decreased). Reasons for dose changes were: adverse events (AEs; 4% Mono; 5% Combo) and lack of efficacy (2% Mono; 1% Combo). Median MTX dose for Combo patients was 15.0 mg/week. 63 patients changed MTX dose (median dose change 5.0 mg/week). 28 (8%) of TCZ mono patients added a DMARD during the study. Corticosteroids were used by 57% of Mono and 70% of Combo patients (median prednisone-equivalent dose (at baseline) 7.5 and 5.0 mg/day, respectively). At 6 months, 72% of Mono and 84% of Combo patients were still receiving TCZ. 100 (10%) patients discontinued TCZ in the first 3 months; 94 (10%) in the next 3 months (reasons: lack of efficacy (11% Mono; 27% Combo), AEs (27% Mono; 29% Combo), other reasons (62% Mono; 44% Combo). AEs occurred in 53% of patients (Table 1) . Infections were less common in Mono patients. No gastrointestinal perforations were reported. Conclusion: In clinical practice, 37% of patients started TCZ as monotherapy and most patients continued with TCZ treatment (Mono and Combo) 6 months after initiation. TCZ was well tolerated in both groups.
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